X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
aged (10) 10
index medicus (10) 10
middle aged (10) 10
female (9) 9
oncology (9) 9
adult (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
disease-free survival (8) 8
breast cancer (7) 7
chemotherapy (7) 7
male (6) 6
survival (5) 5
survival rate (5) 5
trastuzumab (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
aged, 80 and over (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
breast neoplasms - drug therapy (4) 4
breast neoplasms - pathology (4) 4
cancer (4) 4
cancer therapies (4) 4
gebfra science (4) 4
hematology (4) 4
metastases (4) 4
metastasis (4) 4
receptor, erbb-2 - analysis (4) 4
rituximab (4) 4
studies (4) 4
analysis (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antineoplastic agents (3) 3
breast neoplasms - chemistry (3) 3
capecitabine (3) 3
care and treatment (3) 3
combination (3) 3
cytotoxicity (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
drug therapy (3) 3
fluorouracil - administration & dosage (3) 3
fluorouracil - analogs & derivatives (3) 3
follow-up studies (3) 3
lymphoma, mantle-cell - drug therapy (3) 3
maytansine - analogs & derivatives (3) 3
prospective studies (3) 3
quality of life (3) 3
quinazolines - administration & dosage (3) 3
therapy (3) 3
young adult (3) 3
advanced breast cancer (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antimitotic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
article (2) 2
behandlung (2) 2
bendamustine hydrochloride (2) 2
bendamustine hydrochloride - administration & dosage (2) 2
cdk4 (2) 2
cdk4/6 (2) 2
clinical trials (2) 2
comparative analysis (2) 2
cyclophosphamide (2) 2
cyclophosphamide - administration & dosage (2) 2
diarrhea (2) 2
diarrhea - chemically induced (2) 2
doxorubicin - administration & dosage (2) 2
drug administration schedule (2) 2
efficacy (2) 2
epidermal growth factor (2) 2
erbb-2 protein (2) 2
fludarabine (2) 2
functional assessment (2) 2
guidelines (2) 2
hematology, oncology and palliative medicine (2) 2
hypogammaglobulinemia (2) 2
infection - etiology (2) 2
infection control (2) 2
infusions, intravenous (2) 2
kaplan-meier estimate (2) 2
lapatinib (2) 2
leukemia (2) 2
low-grade (2) 2
lymphomas (2) 2
maintenance (2) 2
mammakarzinom (2) 2
maytansine - adverse effects (2) 2
maytansine - therapeutic use (2) 2
medical prognosis (2) 2
medicine, general & internal (2) 2
metastasen (2) 2
methods (2) 2
neoplasm metastasis (2) 2
neutropenia (2) 2
nitrogen mustard compounds - administration & dosage (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2017, Volume 40, Issue 12
Journal Article
European Journal of Haematology, ISSN 0902-4441, 08/2017, Volume 99, Issue 2, pp. 169 - 177
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article
Der Onkologe, ISSN 0947-8965, 8/2017, Volume 23, Issue 8, pp. 645 - 650
Die Adhärenz der Patienten gegenüber der medikamentösen antineoplastischen Therapie wird für den Erfolg der Behandlung immer wichtiger.Es wird ein Überblick... 
Orale Therapie | Medication adherence | Education, patient | Medicine & Public Health | Medikamentenadhärenz | Medizinische Onkologie | Oral therapy | Oncology | Antineoplastische Medikamente | Medical oncology | Antineoplastic agents | Patientenschulung
Journal Article
Der Onkologe, ISSN 0947-8965, 08/2017, Volume 23, Issue 8, p. 645
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00761-017-0237-3... 
Patient education | Analysis | Patient compliance
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2005, Volume 23, Issue 15, pp. 3383 - 3389
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e17549 - e17549
Journal Article
Cancer, ISSN 0008-543X, 03/2014, Volume 120, Issue 5, pp. 642 - 651
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 6517 - 6517
Journal Article
Future Oncology, ISSN 1479-6694, 07/2017, Volume 13, Issue 17, pp. 1463 - 1471
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and... 
everolimus | PAZOREAL | nivolumab | mRCC | Opdivo | metastatic renal cell carcinoma | Votrient | Afinitor | noninterventional | pazopanib | CABOZANTINIB | DIAGNOSIS | GUIDELINES | FOLLOW-UP | OPEN-LABEL | ONCOLOGY | PHASE-3 TRIAL
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, p. 924
Journal Article